{
 "source": "Assay Systems register, https://assay-systems.com/register/",
 "key_tier": "none",
 "data": {
  "url": "https://assay-systems.com/register/ca/grants/r/chipcare-corporation/",
  "assay_record": "ASY-CA-09I4FP915W",
  "summary": "6 federal grant and contribution agreements worth $1.3M with ChipCare Corporation, 2020–2020.",
  "name": "ChipCare Corporation: federal grants and contributions",
  "register": "",
  "dates": [],
  "tiles": [],
  "sections": [],
  "figures": [
   {
    "value": "6",
    "label": "agreements"
   },
   {
    "value": "$1.3M",
    "label": "value"
   },
   {
    "value": "2",
    "label": "departments"
   },
   {
    "value": "5",
    "label": "programs"
   }
  ],
  "text": [
   "RRRF funding will be used to support Recipients to address the impacts of the COVID-19 pandemic.",
   "The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.",
   "The funding provided by the IAP program is intended to assist innovative small and medium-sized enterprises in the start-up phase that cannot access existing commercial support related to COVID-19.",
   "The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.",
   "Growing evidence suggests that T-cell immunity against the virus is long-lasting and protective against re-infection. ChipCare is investigating a potential assay that will help identify individuals who have been exposed to a SARS corona virus in the past and may therefore have immunity to SARS-CoV2. The purpose of this project is to establish the clinical need, research appropriate markers, define the market opportunity and requirements for such an assay and to assess the suitability of such an assay for use in point-of-care settings using ChipCare’s platform.",
   "ChipCare is developing a novel point of care platform for the differential diagnosis of infectious diseases. The platform is initially targeted for the North American market. This project is to establish a business plan and market entry strategy for a research use only (RUO) version of the platform for launch in 2021."
  ],
  "records": [
   {
    "name": "grants and contributions register",
    "url": "https://assay-systems.com/register/ca/grants/"
   },
   {
    "name": "Spadina–Fort York",
    "url": "https://assay-systems.com/register/ca/grants/riding/35101-spadina-fort-york/"
   },
   {
    "name": "Federal Economic Development Agency for Southern Ontario",
    "url": "https://assay-systems.com/register/ca/grants/department/federal-economic-development-agency-for-southern-ontario/"
   },
   {
    "name": "National Research Council Canada",
    "url": "https://assay-systems.com/register/ca/grants/department/national-research-council-canada/"
   }
  ],
  "cite_as": "Assay Systems, \"ChipCare Corporation: federal grants and contributions\", https://assay-systems.com/register/ca/grants/r/chipcare-corporation/"
 }
}